VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits?

VanEck Pharmaceutical ETF (PPH) is favored over VanEck Biotech ETF (BBH) for its lower volatility, 2.0% dividend yield versus 0.4%, and stronger long-term performance, including 10-year annualized returns of 8.8% versus 8.1%. PPH's five-year maximum drawdown was 20.3%, materially shallower than BBH's 39.3%, while its AUM of $995.9M is more than double BBH's $458.7M. BBH has led recently, returning 38.6% over one year and 25.8% year-to-date in 2026, versus PPH's 25.6% and 8.5%, respectively.

Analysis

The relevant exposure is not “pharma versus biotech” but mega-cap metabolic/oncology duration versus idiosyncratic pipeline and M&A optionality. PPH’s concentration makes it materially dependent on LLY and, indirectly, NVO maintaining GLP-1 volume, pricing and manufacturing upside; any evidence of slower prescription growth, Medicare negotiation pressure, or supply normalization could compress the basket despite its defensive beta. BBH’s apparent diversification by capitalization is offset by high active exposure to AMGN, GILD and VRTX, whose earnings paths are driven by a smaller set of franchise and clinical milestones.

After biotech’s sharp relative run, the more actionable question is whether earnings revisions validate the move over the next 1-3 months. BBH can continue to outperform if deal activity broadens beyond large-cap acquirers and lower rates sustain long-duration pipeline valuations, but it is vulnerable to risk-off and binary trial/regulatory setbacks; its historical drawdown profile implies that ETF-level “diversification” does not eliminate event risk. PPH is likely the better 6-18 month defensive healthcare allocation only if LLY/NVO valuation premiums are supported by upward estimates rather than multiple expansion.

Consensus is likely over-weighting trailing volatility and under-weighting concentration. PPH’s lower realized beta may reverse quickly in a GLP-1 de-rating because its two largest obesity-exposed holdings represent a dominant share of incremental sector earnings expectations. Conversely, BBH’s mid-cap exposure provides the cleaner upside convexity to an easing-cycle/M&A regime, but this requires credit spreads to remain contained and biotech IPO/follow-on financing windows to stay open.

Key Decisions for Investors

• Use a 1-3 month relative-value expression: long BBH / short PPH in equal-dollar terms only on a pullback in BBH, targeting further biotech estimate-revision breadth; risk-manage at a 7% adverse move in the relative spread or a material widening in high-yield credit spreads.
• For defensive healthcare exposure over 6-18 months, prefer a selectively hedged PPH position rather than unhedged size: pair long PPH with puts on LLY or a short LLY overlay if GLP-1 prescription-growth data decelerate. The thesis is falsified by sustained LLY/NVO upward guidance revisions that keep valuation support intact.
• Do not treat PPH as a broad low-volatility healthcare substitute. Monitor quarterly LLY and NVO volume/pricing commentary, Medicare drug-pricing developments, and manufacturing-capacity updates; negative revisions in any two would warrant reducing PPH despite stable headline ETF flows.
• Maintain AMGN, GILD and VRTX as event-driven watch names rather than broad BBH proxies. Add BBH exposure only if clinical/regulatory calendars and announced acquisition financing support a widening M&A premium; absent that evidence, the article’s performance comparison is not a standalone trade signal.